Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TGM2 | P21980 | 10/20 | 0.41 |
| ▸ | F13A1 | P00488 | 8/20 | 0.41 |
| ▸ | TGM1 | P22735 | 5/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5000197 | 0.93 | GPR119 (0.48) | GPR119POLBTGM2F13A1TGM1 | |
| SCHEMBL27153102 | 0.80 | GPR119 (0.41) | GPR119POLBTGM2F13A1TGM1 | |
| Trifluoromethanesulfonic Acid SCHEMBL5809482 | 0.71 | TGM2 (0.39) | GPR119TGM2F13A1TGM1MAPT | |
| SCHEMBL27628990 | 0.70 | TGM2 (0.46) | GPR119POLBTGM2F13A1TGM1 | |
| SCHEMBL2247362 | 0.70 | USP2 (0.49) | GPR119TGM2F13A1TGM1MAPT | |
| SCHEMBL31170642 | 0.69 | GPR119 (0.44) | GPR119POLBTGM2F13A1TGM1 | |
| SCHEMBL18425705 | 0.69 | GPR119 (0.44) | GPR119POLBTGM2F13A1TGM1 | |
| SCHEMBL31261849 | 0.69 | GPR119 (0.39) | GPR119POLBTGM2F13A1TGM1 | |
| SCHEMBL31261860 | 0.69 | POLB (0.43) | GPR119POLBTGM2F13A1TGM1 | |
| SCHEMBL1441261 | 0.68 | ALDH1A1 (0.50) | POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7425638-B2 | Cis-imidazolines | HOFFMANN-LA ROCHE INC. (US) | 2008-09-16 | — | — | US | disclosed |
| EP-1638942-A1 | CIS-2,4,5-TRIARYL-IMIDAZOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-29 | — | — | EP | disclosed |
| WO-2005003097-A1 | CIS-2,4,5-TRIARYL-IMIDAZOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-13 | — | — | WO | disclosed |
| US-20040259884-A1 | Cis-imidazolines | HALEY GREGORY JAY (US) | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259884-A1 | Cis-imidazolines | TP53, MDM2, TP53BP1 | GPR119 1986/4885POLB 3364/4885TGM2 2410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.